Regeneron’s Cemdisiran Applications Accepted by FDA and EMA

Key Facts

1The FDA and EMA have accepted regulatory applications for cemdisiran as a potential therapy for generalized myasthenia gravis.

In a move reflecting the company's push to diversify its pharmaceutical portfolio, Regeneron Pharmaceuticals announced that major health authorities have accepted regulatory applications for cemdisiran. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) accepted the filings for the drug as a potential therapy for generalized myasthenia gravis. This acceptance marks a significant milestone for the first-in-class siRNA therapy.

Regeneron is seeking to broaden its revenue base beyond its blockbuster drugs EYLEA and Dupixent as competition intensifies in the biotech sector. In comparison, peer company Amgen recently reported a 22% revenue increase in its Q1 earnings according to search data, highlighting the pressure on Regeneron to deliver new catalysts. Analysts are closely watching the company's ability to transition these regulatory milestones into commercial successes to offset potential maturity in its core product lines.

Shares of REGN stood at $654.27 (at close July 02, 2026), having reached a session high of $654.93. Investors should watch for further FDA updates regarding the final review timeline and potential PDUFA dates. Additionally, broader market sentiment may be influenced by upcoming economic data, such as the Dallas Fed Manufacturing Index, which could impact the healthcare sector's performance.